editors letter looking ahead to 2022

What Do YOU Know About the New Generation of Alzheimer’s Drugs?

By | June 30th, 2023

Patients and caregivers: Doctors are asking for your insights, experiences and concerns about this new generation of monoclonal antibody Alzheimer's drugs.

Last week I had the opportunity to be the guest speaker of Grand Rounds at the Memory and Aging Center at the University of California San Francisco. In the audience were doctors, scientists, and health care workers who specialize in neurology. I was told I was an unusual speaker for this regular UCSF event, given that usually, the featured guest is a scientist presenting their latest research.

Complete our survey on
the new generation of
Alzheimer’s drugs here.

Your stories are powerful. And thanks to all of the insights you have shared, I was able to tell the audience about patient and caregiver perspectives on Alzheimer’s they don’t always have access to: with early signs and symptoms, misdiagnoses, and what it means to truly live life with dementia.

After the talk, I spoke with a few of the neurologists, and interestingly, I got a glimpse of some of their biggest shared concerns right now: The landscape of Alzheimer’s treatment is undergoing a major evolution with the approval of two monoclonal antibody drugs — “anti-amyloid” Alzheimer’s drugs Aduhelm and Leqembi — so far.

(In February 2024, Biogen took Aduhelm off the market indefinitely.)

One of the doctors asked me if I had any clues as to how they should be speaking to patients about this new world of Alzheimer’s drugs. It’s an important question, because there are still a lot of unknowns about these drugs, and further, not all patients have easy access to them. It got me thinking how great it would be to get more input from you, our community, so that we could create a report for doctors — driven by what questions you may have — about how they can be more helpful to patients.

So, we’ve designed a quick survey on “The New Alzheimer’s Drugs.” It should only take a few minutes of your time. If you could please take a moment to answer these questions, we will both publish what we learn from you, and we’ll create a guide for medical professionals highlighting patient concerns and questions. (We’ll share that with you, too!) Your information will always remain anonymous and private. Part of our mission is to elevate patient and caregiver insights. We believe that’s the only way to truly understand — and effectively treat — Alzheimer’s disease and other dementias.

Taking an anti-amyloid? New to the idea altogether? Complete our survey and share what you know — and don’t — about this new generation of Alzheimer’s treatments.

UPDATE: 3 March 2024, 9:36 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive accelerated, conditional FDA approval for the treatment of early Alzheimer’s disease in 2021, it is no longer available to new patients. The company announced it would sunset trials in May 2024 and cease supplying the drug to current patients in November 2024.

If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.

Please help support our mission.

One thought on “What Do YOU Know About the New Generation of Alzheimer’s Drugs?

  1. Is it possible that Lequembi will be prescribed “off label” such as for someone with Multiple Systems Atrophy and Pulmonary Fibrosis (not progressing) who has dementia?

Leave a Reply

We are glad you have chosen to leave a comment. Please keep in mind that comments are moderated according to our comment policy.